Medicina Legal, Psiquiatría y Patología
Departamento
University of Innsbruck
Innsbruck, AustriaPublicaciones en colaboración con investigadores/as de University of Innsbruck (24)
2024
-
Relapse in clinically stable adult patients with schizophrenia or schizoaffective disorder: evidence-based criteria derived by equipercentile linking and diagnostic test accuracy meta-analysis
The Lancet Psychiatry, Vol. 11, Núm. 1, pp. 36-46
2023
-
A second update on mapping the human genetic architecture of COVID-19
Nature
-
Editorial: Biopsychosocial complexity research
Frontiers in Psychiatry
2022
-
Scalability of the Positive and Negative Syndrome Scale in first-episode schizophrenia assessed by Rasch models
Acta Psychiatrica Scandinavica, Vol. 146, Núm. 1, pp. 21-35
-
The transition from adolescence to adulthood in patients with schizophrenia: Challenges, opportunities and recommendations
European Neuropsychopharmacology, Vol. 59, pp. 45-55
2021
-
Baseline Levels of C-Reactive Protein and Proinflammatory Cytokines Are Not Associated with Early Response to Amisulpride in Patients with First Episode Psychosis: The OPTiMiSE Cohort Study
Schizophrenia Bulletin Open, Vol. 2, Núm. 1
-
Symptom Remission and Brain Cortical Networks at First Clinical Presentation of Psychosis: The OPTiMiSE Study
Schizophrenia bulletin, Vol. 47, Núm. 2, pp. 444-455
2019
-
AMPA receptor GluA2 subunit defects are a cause of neurodevelopmental disorders
Nature Communications, Vol. 10, Núm. 1
-
Correction: Stratification and prediction of remission in first-episode psychosis patients: the OPTiMiSE cohort study (Translational Psychiatry, (2019), 9, 1, (20), 10.1038/s41398-018-0366-5)
Translational Psychiatry
-
Stratification and prediction of remission in first-episode psychosis patients: the OPTiMiSE cohort study
Translational Psychiatry, Vol. 9, Núm. 1
2018
-
Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study
The Lancet Psychiatry, Vol. 5, Núm. 10, pp. 797-807
-
Is it time to revise the diagnostic criteria for apathy in brain disorders? The 2018 international consensus group
European Psychiatry, Vol. 54, pp. 71-76
2017
-
Bitopertin in Negative Symptoms of Schizophrenia—Results From the Phase III FlashLyte and DayLyte Studies
Biological Psychiatry, Vol. 82, Núm. 1, pp. 8-16
2015
-
Exploring the relationship between lifestyles, diets and genetic adaptations in humans
BMC Genetics, Vol. 16, Núm. 1
-
Magnetic resonance imaging and the prediction of outcome in first-episode schizophrenia: A review of current evidence and directions for future research
Schizophrenia Bulletin, Vol. 41, Núm. 3, pp. 574-583
-
Modeling determinants of medication attitudes and poor adherence in early nonaffective psychosis: Implications for intervention
Schizophrenia Bulletin, Vol. 41, Núm. 3, pp. 584-596
-
The optimization of treatment and management of schizophrenia in Europe (OPTiMiSE) trial: Rationale for its methodology and a review of the effectiveness of switching antipsychotics
Schizophrenia Bulletin, Vol. 41, Núm. 3, pp. 549-558
-
The promise of biological markers for treatment response in first-episode psychosis: A systematic review
Schizophrenia Bulletin, Vol. 41, Núm. 3, pp. 559-573
2014
-
Efficacy and safety of adjunctive bitopertin (10 and 20mg) versus placebo in subjects with persistent predominant negative symptoms of schizophrenia treated with antipsychotics - Results from the Phase III FlashLyte Study
Schizophrenia Research, Vol. 158, Núm. 1-3
-
Schizophrenia-Time to commit to policy change
Schizophrenia Bulletin, Vol. 40, Núm. SUPPL. 3